UOC
ITOS

UBS O'Connor’s iTeos Therapeutics ITOS Stock Holding History

UBS O'Connor’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-125,589
Closed -$965K – 402
2024
Q4 		$965K Buy
125,589
+59,649
+90% +$513K 0.02% 231
2024
Q3 		$673K Buy
65,940
+30,617
+87% +$467K 0.02% 320
2024
Q2 		$524K Buy
+35,323
New +$506K 0.01% 364
2023
Q4 		– Sell
-59,764
Closed -$654K – 560
2023
Q3 		$654K Buy
59,764
+8,000
+15% +$102K 0.01% 369
2023
Q2 		$685K Sell
51,764
-17,536
-25% -$250K 0.01% 417
2023
Q1 		$943K Buy
+69,300
New +$1.24M 0.02% 415
2022
Q4 		– Sell
-57,500
Closed -$1.09M – 164
2022
Q3 		$1.09M Buy
57,500
+5,000
+10% +$115K 0.01% 736
2022
Q2 		$1.08M Buy
+52,500
New +$1.25M 0.01% 749

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS O'Connor's ITOS Position: Q1 2025 in Review

UBS O'Connor sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 125,589 shares — an estimated $965K sold.

UBS O'Connor first reported a position in ITOS in Q2 2022 and held it in 8 quarters. The position peaked at $1.09M in Q3 2022. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • UBS O'Connor reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 125,589 iTeos Therapeutics shares in Q1 2025, an estimated $965K.
  • UBS O'Connor first reported a position in iTeos Therapeutics in Q2 2022 and held it in 8 quarters.
  • UBS O'Connor's iTeos Therapeutics position peaked at $1.09M in Q3 2022.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.